A Novel Aspergillus Galactomannan Chemiluminescence Immunoassay: Evaluation for Diagnosis of Invasive Pulmonary Aspergillosis in a Multicenter Controlled Study

Clicks: 16
ID: 333387
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #175 of 187 articles by views in medical mycology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 187 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract The Aspergillus galactomannan chemiluminescence immunoassay (GM–CLIA) is a novel non-culture-based test applied in the detection of GM antigen in serum and bronchoalveolar lavage fluid (BALF). This multicenter, retrospective, and controlled study aims to investigate its diagnostic value for invasive aspergillosis (IA). A total of 246 serum and 228 BALF samples were obtained from IA patients (n = 229) and non-IA (n = 236) patients between March 2023 and July 2024. The performance of GM-CLIA was compared with that of Aspergillus GM sandwich enzyme immunoassay (GM-EIA) through Spearman rank correlation analysis and assessed via sensitivity, specificity, positive/negative predictive values (PPV/NPV), and receiver operating characteristic (ROC) curve analysis. Analytical performance was evaluated through interference, precision, limit of detection (LoD), and cross–reactivity experiments.The sensitivity, specificity, PPV, and NPV of serum GM–CLIA were 93.97%, 97.46%, 97.32%, and 94.26%, respectively. For BALF GM–CLIA, the corresponding values were 93.58%, 95.76%, 95.33%, and 94.17%. ROC analysis yielded high area under the curve (serum: 0.977; BALF: 0.982) with optimal cut–offs of 0.625 (serum) and 0.615 (BALF). The levels of GM by CLIA and EIA (rs = 0.838, P < 0.0001) strongly correlated. No interference was observed from hemoglobulin, bilirubin, or triglycerides at certain concentrations. Repeatability, indoor, and inter-batch precision met predefined criteria, with no cross-reactivity in non–Aspergillus pathogens. The LoD for detecting GM–CLIA was 0.09 ng/mL. In summary, GM–CLIA was evaluated in both sample types, demonstrating high specificity and sensitivity in diagnosing IA. Thus, clinical implementation of CLIA may significantly improve diagnostic efficiency and patient outcomes.
Reference Key
openalex_W7223100649 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yuling Xiao, Shiji Wu, Chongyang Wu, Yu Yuan, Yun Wang, Zhenjia Liu, Dan Zhang, Li Gu, Xinmin Chu, Guibo Song, Bin Shan, Zeshi Liu, Yan Geng, Yi Xie
Are you one of these authors? Claim your profile
Journal medical mycology
Year 2026
DOI
10.1093/mmy/myag062
URL
https://doi.org/10.1093/mmy/myag062
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.